Dermapharm Holding SE

XETRA DMP.DE

Dermapharm Holding SE Operating Income Margin for the year ending December 31, 2023: 16.11%

Dermapharm Holding SE Operating Income Margin is 16.11% for the year ending December 31, 2023, a -32.26% change year over year. Operating Income Ratio is the proportion of a company's operating income to its net sales, measuring the efficiency of its core business operations in generating profits.
  • Dermapharm Holding SE Operating Income Margin for the year ending December 31, 2022 was 23.78%, a -24.88% change year over year.
  • Dermapharm Holding SE Operating Income Margin for the year ending December 31, 2021 was 31.65%, a 83.61% change year over year.
  • Dermapharm Holding SE Operating Income Margin for the year ending December 31, 2020 was 17.24%, a 1.10% change year over year.
  • Dermapharm Holding SE Operating Income Margin for the year ending December 31, 2019 was 17.05%, a -9.21% change year over year.
Key data
Date Operating Income Margin EBT Margin Net Income Margin EBITDA Margin
Market news
Loading...
SV Wall Street
XETRA: DMP.DE

Dermapharm Holding SE

CEO Dr. Hans-Georg Feldmeier
IPO Date April 12, 2018
Location Germany
Headquarters Lil-Dagover-Ring 7
Employees 3,603
Sector Healthcare
Industries
Description

Dermapharm Holding SE, together with its subsidiaries, engages in the off-patent branded pharmaceuticals business in Germany and internationally. It operates through three segments: Branded Pharmaceuticals and Other Healthcare Products, Parallel Import Business, and Herbal Extracts. The company develops, manufactures, licenses, markets, and sells branded generics, over-the-counter drugs, non-prescription natural remedies, and other healthcare products. It also offers healthcare products in the areas of vitamins, minerals, food supplements, dermatology, allergology, pain and inflammation treatment, cardiovascular support, gynecology, and urology primarily under the Dekristol, Dekristolvit, Allergovit, and Tromcardin brands. In addition, the company provides medical devices under the bite away and Herpotherm names; Momekort, a nasal spray used to treat allergy symptoms; and Azedil, a nasal spray or eye drop. Further, it imports originator pharmaceuticals under the axicorp brand; and offers herbal extracts and natural active ingredients for phytopharmaceuticals, nutraceuticals, and cosmetics. It serves pharmaceutical wholesalers, pharmacies, hospitals, and health food stores. The company was founded in 1991 and is headquartered in Grünwald, Germany. Dermapharm Holding SE is a subsidiary of Themis Beteiligungs-Aktiengesellschaft.

StockViz Staff

February 5, 2025

Any question? Send us an email